KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2020 - 2025)

Sarepta Therapeutics has reported Non-Current Deffered Revenue over the past 9 years, most recently at $83.9 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 74.18% year-over-year to $83.9 million; the TTM value through Dec 2025 reached $83.9 million, down 74.18%, while the annual FY2025 figure was $83.9 million, 74.18% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $83.9 million at Sarepta Therapeutics, down from $325.0 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $641.5 million in Q1 2021 and troughed at $83.9 million in Q4 2025.
  • A 5-year average of $450.4 million and a median of $485.0 million in 2022 define the central range for Non-Current Deffered Revenue.
  • On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2025 and fell as far as 74.18% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $574.2 million in 2021, then decreased by 15.54% to $485.0 million in 2022, then decreased by 9.9% to $437.0 million in 2023, then fell by 25.63% to $325.0 million in 2024, then tumbled by 74.18% to $83.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SRPT at $83.9 million in Q4 2025, $325.0 million in Q1 2025, and $325.0 million in Q4 2024.